has approved Zepbound ® (tirzepatide) as the first and only prescription treatment for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Zepbound is intended to help ...
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea. Research shows that it considerably improves the level of AHI in patients with ...
which assessed the impact of tirzepatide (Zepbound, Eli Lilly) on apnea-hypopnea index and body weight for adults with obesity and obstructive sleep apnea (OSA); and a prespecified analysis of the ...
Tirzepatide works by activating receptors of hormones produced by the intestine to reduce hunger. It can result in weight loss, which may improve sleep apnea. Hypoglossal nerve stimulation is a ...
UAE -- The U.S. Food and Drug Administration (FDA) approved lately Tirzepatide, produced by Eli Lilly, as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...